A share price of Quince Therapeutics Inc [QNCX] is currently trading at $1.43, up 19.17%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The QNCX shares have gain 22.22% over the last week, with a monthly amount glided 69.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Quince Therapeutics Inc [NASDAQ: QNCX] stock has seen the most recent analyst activity on March 24, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $10.
Quince Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.51 and $2.45. Quince Therapeutics Inc [NASDAQ: QNCX] shares were valued at $1.43 at the most recent close of the market.
Analyzing the QNCX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -1.73 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2633 points at the first support level, and at 1.0967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5233, and for the 2nd resistance point, it is at 1.6167.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Quince Therapeutics Inc [NASDAQ:QNCX] is 4.05. In addition, the Quick Ratio stands at 4.05 and the Cash Ratio stands at 0.93.
Transactions by insiders
Recent insider trading involved Thye Dirk, CEO AND CHIEF MEDICAL OFFICER, that happened on Aug 30 ’24 when 77000.0 shares were purchased. CEO AND CHIEF MEDICAL OFFICER, Thye Dirk completed a deal on Aug 29 ’24 to buy 77500.0 shares. Meanwhile, PRESIDENT Ryan Charles S. bought 48387.0 shares on Aug 20 ’24.
